Low-dose interleukin 1 and tumor necrosis factor individually stimulate insulin release but in combination cause suppression

Department of Medicine, Veterans Affairs Medical Center, Seattle, WA 98108.

The macrophage-derived cytokines interleukin 1 (IL-1) and tumor necrosis factor (TNF) have direct effects on pancreatic beta cells and have been hypothesized to play important roles in the autoimmune beta cell lesion of type I diabetes because of two major effects on beta cells: altered insulin secretion and beta cell cytotoxicity. High doses of IL-1 are cytotoxic to beta cells and strongly inhibit insulin release; high-dose IL-1 plus TNF acts synergically to suppress further the insulin release. In contrast, we observed that the predominant effect of low-dose IL-1 and TNF when administered separately was the stimulation of insulin release. We therefore asked whether the combination of low-dose IL-1 plus TNF would act synergistically to stimulate or suppress insulin release. Studies were performed on cultured rat islets and both insulin release and cytotoxicity (51Cr release) were measured. After 2 days of culture, increasing doses of IL-1-25, 50, 75 and 100 ng/l--caused progressively increased cytotoxicity and impaired insulin release. In contrast, the lowest dose of IL-1 tested, 10 ng/l, increased insulin release but was still slightly cytotoxic. Tumor necrosis factor at doses of 10, 25, 62.5, 75 and 100 micrograms/l also was slightly cytotoxic but increased insulin release. The augmented insulin release declined progressively with increasing TNF dose. However the combination of insulin stimulatory doses of IL-1 (10 ng/l) and TNF (62.5 micrograms/l) suppressed insulin release. The effects of these two cytokines on insulin release demonstrated a similar pattern after 4 and 6 days of culture.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				D. A. van Waardenburg, T. C. Jansen, G. D. Vos, and W. A. Buurman Hyperglycemia in Children with Meningococcal Sepsis and Septic Shock: The Relation between Plasma Levels of Insulin and Inflammatory Mediators J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3916 - 3921. [Abstract] [Full Text] [PDF]

				M. J. Delano and L. L. Moldawer The Origins of Cachexia in Acute and Chronic Inflammatory Diseases Nutr Clin Pract, February 1, 2006; 21(1): 68 - 81. [Abstract] [Full Text] [PDF]

				R. K. Krishnan, J. M. Hernandez, D. L. Williamson, D. J. O'Gorman, W. J. Evans, and J. P. Kirwan Age-related differences in the pancreatic beta -cell response to hyperglycemia after eccentric exercise Am J Physiol Endocrinol Metab, September 1, 1998; 275(3): E463 - E470. [Abstract] [Full Text] [PDF]

				D. J. Gross, L. Weiss, I. Reibstein, J. van den Brand, H. Okamoto, A. Clark, and S. Slavin Amelioration of Diabetes in Nonobese Diabetic Mice with Advanced Disease by Linomide-Induced Immunoregulation Combined with Reg Protein Treatment Endocrinology, May 1, 1998; 139(5): 2369 - 2374. [Abstract] [Full Text] [PDF]

				Z.-W. Chen, B. Ahren, C.-G. Ostenson, A. Cintra, T. Bergman, C. Moller, K. Fuxe, V. Mutt, H. Jornvall, and S. Efendic Identification, isolation, and characterization of daintain (allograft inflammatory factor 1), a macrophage polypeptide with effects on insulin secretion and abundantly present in the pancreas of prediabetic BB rats PNAS, December 9, 1997; 94(25): 13879 - 13884. [Abstract] [Full Text] [PDF]